BGT 002
Alternative Names: 326E; BGT-002Latest Information Update: 29 Jul 2024
At a glance
- Originator Burgeon Therapeutics
- Class Antihyperlipidaemics; Hepatoprotectants; Small molecules
- Mechanism of Action ATP citrate (pro S) lyase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Non-alcoholic steatohepatitis
- Phase I Hypercholesterolaemia
Most Recent Events
- 18 Jul 2024 Burgeon Therapeutics plans a phase I trial in Hypercholesterolemia (In volunteers) in China (PO)(ChiCTR2200057793)
- 08 Jun 2024 Pharmacokinetics, efficacy and adverse event data from a phase Ib/II trial in Non-alcoholic steatohepatitis presented at the European Association for the Study of the Liver (EASL-2024)
- 05 Jun 2024 Updated efficacy, adverse events and pharmacokinetics results from a phase I/II trial in Non-alcoholic steatohepatitis presented at the European Association for the Study of the Liver Congress 2024 (EASL-2024)